{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1196.495","meta":{"versionId":"16","lastUpdated":"2021-09-09T01:01:05.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495","version":"20210909","name":"ICS LABA LAMA Preparations","status":"active","date":"2021-09-09T01:01:05-04:00","publisher":"NHLBI Implementation Science and Health Care Innovation Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","concept":[{"code":"1945039","display":"14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler"},{"code":"1945044","display":"14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]"},{"code":"1945047","display":"30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler"},{"code":"1945048","display":"30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]"}]}]}}